4Teen4 Pharmaceuticals GmbH

Based in Hennigsdorf, Germany, and founded in 2013 by Dr. Andreas Bergmann (CEO), 4Teen4 Pharmaceuticals GmbH, formerly known as Sphingotec Therapeutics GmbH, operates as a provider of precision medicine targeting critical cardiac and vascular conditions to hospitals and intensive care units in Europe and the U. S. In November 2025, 4Teen4 Pharmaceuticals GmbH raised EUR 55 million in series C funding from other unspecified investors.

4Teen4 Pharmaceuticals GmbH specializes in precision medicine for critical cardiac and vascular conditions. Their flagship product, Procizumab (PCZ), is a humanized monoclonal antibody designed to inhibit circulating Dipeptidyl Peptidase 3 (cDPP3), a key mediator in shock and circulatory failure. This product targets acute cardiovascular complications, particularly cardiogenic shock, seen in patients suffering from conditions such as acute myocardial infarction, acute decompensated heart failure, sepsis, and major surgeries. The company is in the clinical development phase, with a Phase 1b/2a trial scheduled to begin in Q1 2025 to establish dosing regimens for future studies.

4Teen4 Pharmaceuticals operates with a B2B model, focusing on partnerships with hospitals, healthcare providers, and research institutions. Revenue generation is expected through the commercialization of Procizumab, with pricing reflecting the critical nature of the therapy. The company anticipates long-term partnerships and bulk purchasing agreements for treating cardiogenic shock patients. The company plans to utilize the November 2025 funding to broaden the PROCARD 2a study throughout Europe and to facilitate its upcoming expansion in the US, enhancing operational preparedness before the pivotal trial begins.